Regulatory Affairs Associates Awarded NIH Grant to Assis with Eye Experimental Drugs and Medical Devices

FOR IMMEDIATE RELEASE
(Free-Press-Release.com) October 17, 2011 -- Farmington Hills, MI - October 13, 2011- The National Institutes of Health (NIH) has awarded a contract to Regulatory Affairs Associates (RAA) of Farmington Hills, Michigan to undertake a one-year program with drug companies who specialize in eye experimental drugs and medical devices.

RAA was selected for its many years of experience, dedicated staff, and innovative approach to drug development. RAA has worked with many cancer development drugs and recently guided an NCI sponsored oral oncology drug through FDA oversight to clinical testing.

Oakland County Executive L. Brooks Patterson said “We are thrilled the National Cancer Institute awarded this important contract to a Farmington Hills company. The staff of this respected business will help companies from across the country access the resources of our region, ensuring Regulatory Affairs Associates’ continued growth. This contract from this most prestigious Cancer Institute is another example of how Oakland County’s Medical Main Street is helping shape the future of the life science industry in Michigan and beyond. Together we are reshaping the future for Michigan.”
Every drug researched and developed through National Institutes of Health’s (NiH) program funding must be approved by FDA in order to become a treatment option for physicians and patients. The expert FDA regulatory advisors at RAA know the testing and data presentations that FDA requires. Now they will be available to programs that have NIH research funding. This reduces the time and money needed for testing by creating collaborations between FDA and the NIH researchers. It is expected to bring more cancer cures to patients sooner.

RAA will direct NIH recipients to navigate the complicated regulatory path to FDA approval and commercial acceptance. It is one of the NIH’s translational medicine implementation practices; to move break-through drug research from the research labs, to controlled clinical tests, to medical practice for eye patients. Researchers will begin receiving this assistance very quickly.

The NIH drug programs will follow a very simple application process to take advantage of this opportunity. The projects will be reviewed and regulatory experts assigned to create a regulatory process tailored to each project. Progress will be tracked and improved upon as the projects proceed through their rigorous scientific and medical testing process. The process will be benchmarked to ensure ‘best practices’ results; offers researchers increased opportunities to engage with knowledgeable and innovative drug developers. To find out more about this program, please contact Stephen Goldner at sgoldner@regaffirs.net or www.regaffairs.net :
Stephen Goldner
President
Regulatory Affairs Associates

experimental eye drugs     eye medications     NIH Grant     regulatory affairs consultants